Figure 4 and 5 Real-time polymerase chain reaction with SYBR Green master mix were used to quantify the expression levels of 84 genes ontologically related and regulated by TGF β /BMP Signalling pathway, or the 84 genes of Signal Transduction Pathway Finder specific arrays (SA Biosciences, Frederick, MD). The heat-map shows absolute mRNA copy numbers which were calculated from PCR cycle thresholds (Cts, Fig. 4). For example, on the color coded log2 scale, a value of 10 represents 2¹⁰ or 1024 transcripts. Two endogenous controls, GAPDH and ACTB, were used for normalization. Functional gene clustering (with major groups according to the array manual) indicated at right. In the Signal Transduction Pathway Finder Array (Fig. 5), the fold expression differences were analyzed through the SA Biosciences webpage, then transferred into MATLAB and visualized with the Bioinformatics Toolbox Clustergram function. All experiments were run in triplicates.

Figure 6 Parallel triplicate experiments were plated and synchronized as described in the Material and Methods section. A-083-01 (5 μ M) pre-treatment were used (30 minutes) on selected samples followed by LAM and TGF β 1 exposure alone and in combination with the inhibitor. Samples were harvested after 4-hour incubation to enhance the stable expressional profile changes. Selected genes were assayed on cDNA library generated (Materials and Methods) by ABI TaqMan probes (Supplemental Table 2) on ABI 7900 HT Fast Real Time QPCR instrument. The results were transferred to Excel (Microsoft) and graphed with error bars generated by standard deviation of Ct values from the three independent experiments.

Supplemental Material: The plate is normalized to the average of 5 house-keeping genes B2M, HPRT1, RPL13A, GAPGH, and ACTB. The p=0.001 and below was considered highly significant. From the original description and functional grouping of product specification sheet four groups

were created by combining the Transcription Factors and Regulators (group 4, 21 genes) with the Genes Involving in Cellular and Developmental Processes (group 5, 28 genes).

The Venn analysis was performed through (<u>http://www.pangloss.com/seidel/Protocols/venn4.cgi</u>) site. The generated group lists (Supplemental Table 1) were used to create the figure (Supplemental Fig. 1) in which genes are represented by squares, grouped according to their function and coloured according to their expression levels in MCF-7 as compared to MCF-10A.

The SuperArray (SA) results were validated with individual TaqMan assays designed against selective targets from the same cDNA pools that were used to generate the array data sets (Supplemental Table 2). Expressional fold changes are shown. From the total of 33 validated genes, 11 presented. The TaqMan data considered more accurate, because of specifically targeted assays vs. the less sensitive SYBR Green detection system/chemistry employed in Super Arrays. The difference between the two systems is greater when expressional changes are higher. Some of the genes are not analyzed in all experiments (N/A) due to depletion of representative cDNA archives.

Gene Expressional Differences in MCF-7 vs. MCF-10A cells, Venn Groups





Supplemental Figure 1

Supplemental Table 1.

Change of Basal Gene Expressional values in MCF-7 as compared to MCF-10A cell line.

Gene # /Position	GeneBank	Symbol	Up/Down Regulation	p-Value	Description
Venn	Group a				
01 /A01	NM 001105	ACVR1	-4.96	0.0000	Activin A receptor, type I
02 /A02	NM 001616	ACVR2A	-2.62	0.0007	Activin A receptor, type IIA
03 /A03	NM 000020	ACVRL1	-1.25	0.7013	Activin A receptor type II-like 1
05 /A05	NM_020547	AMHR2	1.08	0.8043	Anti-Mullerian hormone receptor, type II
16 /B04	NM_004329	BMPR1A	-2.40	0.0011	Bone morphogenetic protein receptor, type IA
17 /B05	NM_001203	BMPR1B	-7.37	0.0000	Bone morphogenetic protein receptor, type IB
36 /C12	NM_000557	GDF5	-1.38	0.4911	Growth differentiation factor 5 (cartilage-derived morphogenetic protein-1)
37 /D01	NM_001001557	GDF6	1.12	0.9002	Growth differentiation factor 6
38 /D02	NM_182828	GDF7	-1.52	0.4995	Growth differentiation factor 7
53 /E05	NM_020997	LEFTY1	-1.76	0.0529	Left-right determination factor 1
59 /E11	NM_018055	NODAL	-3.62	0.1290	Nodal homolog (mouse)
77 /G05	NM_003238	TGFB2	-4.52	0.0566	Transforming growth factor, beta 2
78 /G06	NM_003239	TGFB3	-1.12	0.2902	Transforming growth factor, beta 3
80 /G08	NM_004612	TGFBR1	-2.53	0.0000	Transforming growth factor, beta receptor I (activin A receptor type II-like kinase, 53kDa)
81 /G09	NM_003242	TGFBR2	-36.72	0.0001	Transforming growth factor, beta receptor II (70/80kDa)
82 /G10	NM_003243	TGFBR3	-268.88	0.0000	Transforming growth factor, beta receptor III (betaglycan, 300kDa)
83 /G11	NM_004257	TGFBRAP1	-1.34	0.1339	Transforming growth factor, beta receptor associated protein 1

Venn Group b

06 /A06	NM_012342	BAMBI	25.26	0.0000	BMP and activin membrane-bound inhibitor homolog (Xenopus laevis)
15 /B03	NM_133468	BMPER	11.24	0.0000	BMP binding endothelial regulator
19 /B07	NM_001789	CDC25A	5.45	0.0018	Cell division cycle 25A
21 /B09	NM_004936	CDKN2B	651.26	0.0000	Cyclin-dependent kinase inhibitor 2B (p15, inhibits CDK4)
22 /B10	NM_005454	CER1	-1.68	0.4798	Cerberus 1, cysteine knot superfamily, homolog (Xenopus laevis)
27 /C03	NM_000099	CST3	-4.81	0.0010	Cystatin C (amyloid angiopathy and cerebral hemorrhage)
31 /C07	NM_004116	FKBP1B	-14.45	0.0001	FK506 binding protein 1B, 12.6 kDa
42 /D06	NM_002166	ID2	1.08	0.5613	Inhibitor of DNA binding 2, dominant negative helix- loop-helix protein
58 /E10	NM_005380	NBL1	-13.16	0.0000	Neuroblastoma, suppression of tumorigenicity 1

Venn Group f

34 /C10	NM_016204	GDF2	-1.27	0.6842	Growth differentiation factor 2
35 /C11	NM_020634	GDF3	1.10	0.8533	Growth differentiation factor 3
54 /E06	NM_000627	LTBP1	-9.20	0.0000	Latent transforming growth factor beta binding protein 1
55 /E07	NM_000428	LTBP2	-16.70	0.0003	Latent transforming growth factor beta binding protein 2
56 /E08	NM_003573	LTBP4	-7.69	0.0000	Latent transforming growth factor beta binding protein 4

Venn Group g

26 /C02	NM_000090	COL3A1	19.06	0.0116	Collagen, type III, alpha 1 (Ehlers-Danlos syndrome type IV, autosomal dominant)
29 /C05	NM_000118	ENG	-76.91	0.0000	Endoglin (Osler-Rendu-Weber syndrome 1)
63 /F03	NM_002658	PLAU	-163.80	0.0000	Plasminogen activator, urokinase
65 /F05	NM_000602	SERPINE1	-48.87	0.0004	Serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1
79 /G07	NM_000358	TGFBI	-246.19	0.0000	Transforming growth factor, beta-induced, 68kDa

Venr	n Group h				
10 /A10	NM_001201	BMP3	1.12	0.7571	Bone morphogenetic protein 3 (osteogenic)
11 /A11	NM_130851	BMP4	1.19	0.2907	Bone morphogenetic protein 4
12 /A12	NM_021073	BMP5	4.80	0.5417	Bone morphogenetic protein 5
13 /B01	NM_001718	BMP6	2.82	0.0201	Bone morphogenetic protein 6
14 /B02	NM_001719	BMP7	2234.86	0.0000	Bone morphogenetic protein 7 (osteogenic protein 1)
18 /B06	NM_001204	BMPR2	-3.38	0.0003	Bone morphogenetic protein receptor, type II (serine/threonine kinase)
61 /F01	NM_000475	NR0B1	-5.73	0.0319	Nuclear receptor subfamily 0, group B, member 1
74 /G02	NM_000660	TGFB1	-1.38	0.0509	Transforming growth factor, beta 1 (Camurati- Engelmann disease)

Venn Group i

veni	i Group i				
20 /B08	NM_000389	CDKN1A	-2.26	0.0000	Cyclin-dependent kinase inhibitor 1A (p21, Cip1)
23 /B11	NM_003741	CHRD	1.84	0.0371	Chordin
28 /C04	NM_004405	DLX2	-2.03	0.0308	Distal-less homeobox 2
30 /C06	NM_005241	EVI1	-2.15	0.1681	Ecotropic viral integration site 1
32 /C08	NM_005252	FOS	2.08	0.0136	V-fos FBJ murine osteosarcoma viral oncogene homolog
39 /D03	NM_173849	GSC	43.78	0.0005	Goosecoid
40 /D04	NM_022740	HIPK2	-1.59	0.0486	Homeodomain interacting protein kinase 2
41 /D05	NM_002165	ID1	-2.84	0.0004	Inhibitor of DNA binding 1, dominant negative helix- loop-helix protein
51 /E03	NM_002228	JUN	-3.01	0.0015	V-jun sarcoma virus 17 oncogene homolog (avian)
52 /E04	NM_002229	JUNB	-1.70	0.0223	Jun B proto-oncogene
57 /E09	NM_002467	MYC	-1.72	0.0030	V-myc myelocytomatosis viral oncogene homolog (avian)
60 /E12	NM_005450	NOG	-90.39	0.0000	Noggin
64 /F04	NM_001754	RUNX1	1.05	0.7004	Runt-related transcription factor 1 (acute myeloid leukemia 1; aml1 oncogene)
66 /F06	NM_005900	SMAD1	-3.95	0.0001	SMAD, mothers against DPP homolog 1 (Drosophila)
67 /F07	NM_005901	SMAD2	-3.01	0.0001	SMAD, mothers against DPP homolog 2 (Drosophila)
68 /F08	NM_005902	SMAD3	-1.61	0.0352	SMAD, mothers against DPP homolog 3 (Drosophila)
69 /F09	NM_005359	SMAD4	-4.54	0.0006	SMAD, mothers against DPP homolog 4 (Drosophila)
70 /F10	NM_005903	SMAD5	-3.29	0.0001	SMAD, mothers against DPP homolog 5 (Drosophila)
71 /F11	NM_020429	SMURF1	-1.12	0.3781	SMAD specific E3 ubiquitin protein ligase 1
72 /F12	NM_003107	SOX4	-3.16	0.0000	SRY (sex determining region Y)-box 4
84 /G12	NM_003244	TGIF	1.37	0.7693	TGFB-induced factor (TALE family homeobox)
76 /G04	NM_006022	TSC22D1	-1.30	0.0283	TSC22 domain family, member 1

Venn Group k

45 /D09	NM_000600	IL6	-4.98	0.0118	Interleukin 6 (interferon, beta 2)
49 /E01	NM_002213	ITGB5	1.05	0.6171	Integrin, beta 5
50 /E02	NM_000889	ITGB7	-2.80	0.0009	Integrin, beta 7
62 /F02	NM_002608	PDGFB	115.14	0.0000	Platelet-derived growth factor beta polypeptide (simian sarcoma viral (v-sis) oncogene homolog)

Venn Group I

	NM_007315	STAT1	3.78	0.0003	Signal transducer and activator of transcription 1,	
73 /G01					91kDa	

Venn Group m

04 /A04	NM_000479	AMH	-1.08	0.3811	Anti-Mullerian hormone
08 /A08	NM_006129	BMP1	-44.45	0.0000	Bone morphogenetic protein 1
09 /A09	NM_001200	BMP2	-290.42	0.0000	Bone morphogenetic protein 2
46 /D10	NM_002191	INHA	1.87	0.0114	Inhibin, alpha
47 /D11	NM_002192	INHBA	-8.30	0.0002	Inhibin, beta A (activin A, activin AB alpha polypeptide)
48 /D12	NM_002193	INHBB	4.73	0.0001	Inhibin, beta B (activin AB beta polypeptide)

Venn Group n

07 /A07	NM_199173	BGLAP	-3.77	0.0001	Bone gamma-carboxyglutamate (gla) protein (osteocalcin)
24 /B12	NM_000088	COL1A1	-1.79	0.1686	Collagen, type I, alpha 1

25 /C01	NM_000089	COL1A2	-1.47	0.3629	Collagen, type I, alpha 2
33 /C09	NM_006350	FST	-2.69	0.0014	Follistatin

Venr	n Group o				
	NM_000618	IGF1	-1.34	0.6914	Insulin-like growth factor 1 (somatomedin C)
43 /D07					
44 /D08	NM_000598	IGFBP3	1.11	0.3014	Insulin-like growth factor binding protein 3
75 /G03	NM_015927	TGFB1I1	-37.76	0.0001	Transforming growth factor beta 1 induced transcript 1
Hous	se-keeping ge	ne controls	4.76	0.0000	Pata 2 miaraglahulin
H01	INIVI_004048	BZIVI	-4.70	0.0000	Beta-2-microglobulin
H02	NM_000194	HPRT1	6.57	0.0003	Hypoxanthine phosphoribosyltransferase 1 (Lesch- Nyhan syndrome)
H03	NM_012423	RPL13A	-2.08	0.0000	Ribosomal protein L13a
H04	NM_002046	GAPDH	-1.10	0.3978	Glyceraldehyde-3-phosphate dehydrogenase
H05	NM_001101	ACTB	1.65	0.0002	Actin, beta

The sub-groups that contained no genes (c, e, j, d in Figure 3) are not listed.

The significant negative values are blue and the positive change is pink. The relevant p-values are highlighted in red.

Table 2

SuperArray Validation with TaqMan Assay (Fold Change)

	MCF-7/MCF-10A		Treatment											
Genes			СП				LAM				ΤGFβ			
	Un-ti cate	u controis	MCF	-10A	MC	F-7	MCF	-10A	MCF-7		MCF-10A		MCF-7	
	SA	TaqMan	SA	TaqMan	SA	TaqMan	SA	TaqMan	SA	TaqMan	SA	TaqMan	SA	TaqMan
BMP2	-290.42	-15.43	-1.08	1.13	1.08	-1.05	-1.43	2.01	3.59	1.68	2.17	1.92	1.35	1.25
BMP7	2234.86	32360.94	1.10	1.59	1.02	1.22	4.33	10.59	2.43	3.28	-2.35	-2.01	1.16	1.84
CDKN2B	651.26	10890.94	1.37	1.03	-1.05	1.08	1.20	-1.02	-1.35	1.68	1.12	1.05	1.51	2.24
FST	-2.69	-2.16	1.05	1.28	1.06	1.36	-2.14	-1.85	-1.25	1.32	16.37	14.93	2.47	3.80
SERPINE1	-48.87	-14.56	1.63	1.71	1.27	1.07	13.95	16.38	5.02	4.61	120.85	118.03	7.56	10.69
PDGFB	115.14	79.71	1.32	N/A	1.02	-1.01	-2.03	N/A	-2.00	N/A	-1.60	N/A	1.57	1.16
PLAU	-163.8	-12.34	2.25	N/A	1.03	-1.39	1.61	N/A	-1.34	N/A	-1.06	N/A	2.67	2.29
TGFBR1	-2.53	-1.44	-1.21	N/A	-1.02	1.09	2.24	N/A	1.20	N/A	1.46	N/A	1.09	-1.09
TGFBR2	-36.72	-7.00	1.31	N/A	-1.01	N/A	-2.06	N/A	-1.09	N/A	-1.81	N/A	1.21	N/A
TGFBR3	-268.88	-67.21	1.09	N/A	-1.00	N/A	-1.45	N/A	1.74	N/A	-3.54	N/A	-1.06	N/A
TGFBI	-246.19	-39.46	1.10	N/A	1.06	N/A	-1.44	N/A	-1.50	N/A	1.36	N/A	1.12	N/A

TaqMan Probes Used:

BMP2	Hs00154192_m1	CCND1	Hs00277039_m1
BMP7	Hs00233476_m1	FASN	Hs00188012_m1
CDKN2B	Hs00793225_m1	FN1	Hs00415006_m1
FST	Hs00246260_m1	IGFBP3	Hs00426287_m1
SERPINE1	Hs00167155_m1	MMP10	Hs00233987_m1
PDGFB	Hs00234042_m1	MYC	Hs00905030_m1
PLAU	Hs00170182_m1	NOG	Hs00271352_m1
TGFBR1	Hs00610319_m1		
TGFBR2	Hs00559661_m1		
TGFBR3	Hs00234259_m1		
TGFBI	Hs00165908_m1		